Проатерогенные нарушения обмена липидов и липопротеидов крови у больных ревматоидным артритом

Автор: Герасимова Е.В., Попкова Т.В., Новикова Д.С.

Журнал: Научно-практическая ревматология @journal-rsp

Статья в выпуске: 3 т.55, 2017 года.

Бесплатный доступ

Ведущее значение в развитии атеросклеротического поражения сосудов при ревматоидном артрите (РА) отводят нарушениям в системе транспорта холестерина крови. В статье проанализирован липидный профиль крови у больных с нелеченым РА. Представлены данные о влиянии воспаления на проатерогенные нарушения обмена липидов и липопротеидов, обозначена необходимость изучения подфракций липопротеидов высокой плотности и их функции - обратного транспорта холестерина у больных РА - как более перспективного метода оценки сердечно-сосудистого риска.

Ревматоидный артрит, обмен липидов и липопротеидов крови, обратный транспорт холестерина

Короткий адрес: https://sciup.org/14945825

IDR: 14945825 | DOI: 10.14412/1995-4484-2017-311-320

Список литературы Проатерогенные нарушения обмена липидов и липопротеидов крови у больных ревматоидным артритом

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 Apr 21;352(16):1685-95 DOI: 10.1056/NEJMra043430
Read TE, Grunfeld C, Kumwenda ZL, et al. Triglyceride-rich lipoproteins prevent septic death in rats. J Exp Med. 1995 Jul 1;182(1):267-72 DOI: 10.1084/jem.182.1.267
Hardardottir I, Kunitake ST, Moser AH, et al. Endotoxin and cytokines increase hepatic messenger RNA levels and serum con centrations of apolipoprotein J (clusterin) in Syrian hamsters. J Clin Invest. 1994 Sep;94(3):1304-9 DOI: 10.1172/JCI117449
Memon RA, Staprans I, Noor M, et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol. 2000 Jun;20(6):1536-42 DOI: 10.1161/01.ATV.20.6.1536
Haas MJ, Mooradian AD. Regulation of high-density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovascular disease. Diabetes Metab Res Rev. 2010 Feb;26(2):90-9 DOI: 10.1002/dmrr.1057
Straub RH, Cutolo M, Buttgereit F, Pongratz G. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med. 2010 Jun;267(6):543-60 DOI: 10.1111/j.1365-2796.2010.02218.x
McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009 Mar 3;119(8):1135-45 DOI: 10.1161/CIRCU-LATI0NAHA.108.810721
Wu Y, Cui J, Bao X, et al. Triptolide attenuates oxidative stress, NF-kappaB activation and multiple cytokine gene expression in murine peritoneal macrophage. Int J Mol Med. 2006 Jan;17(1):141-50.
Kralova A, Kralova Lesna I, Poledne R. Immunological aspects of atherosclerosis. Physiol Res. 2014;63 Suppl 3:S335-42.
Lahoute C, Herbin O, Mallat Z, Tedgui A. Adaptive immunity in atherosclerosis: mechanisms and future therapeutic targets. Nat Rev Cardiol. 2011 Jun;8(6):348-58 DOI: 10.1038/nrcardio.2011.62
Adibhatla RM, Dempsy R, Hatcher JF. Integration of cytokine biology and lipid metabolism in stroke. FrontBiosci. 2008 Jan 1;13:1250-70.
Akita K, Isoda K, Shimada K, Daida H. Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice. J Am Heart Assoc. 2015 Mar 13;4(3):e001469 DOI: 10.1161/JAHA.114.001469
Jovinge S, Ares MP, Kallin B, Nilsson J. Human monocytes/macrophages release TNF-alpha in response to Ox-LDL. Arterioscler Thromb Vasc Biol. 1996 Dec;16(12):1573-9 DOI: 10.1161/01.ATV.16.12.1573
Niemann-Jönsson A, Dimayuga P, Jovinge S, et al. Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-alpha expression. Arterioscler Thromb Vasc Biol. 2000 Oct;20(10):2205-11 DOI: 10.1161/01.ATV.20.10.2205
Zhou Z, Connell MC, MacEwan DJ. TNFR1-induced NF-kappaB, but not ERK, p38MAPK or JNK activation, mediates TNF-induced ICAM-1 and VCAM-1 expression on endothelial cells. Cell Signal. 2007 Jun;19(6):1238-48 DOI: 10.1016/j.cell-sig.2006.12.013
Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993 Jan 1;259(5091):87-91 DOI: 10.1126/science.7678183
Kaplon-Cieslicka A, Postula M, Rosiak M, et al. Association of adipokines and inflammatory markers with lipid control in type 2 diabetes. Pol Arch Med Wewn. 2015;125(6):414-23. Epub 2015 May 15 DOI: 10.20452/pamw.2880
Jovinge S, Hamsten A, Tornvall P, et al. Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism. 1998 Jan;47(1):113-8 DOI: 10.1016/S0026-0495(98)90203-7
Ahmed W, Orasanu G, Nehra V, et al. High-density lipoprotein hydrolysis by endothelial lipase activates PPARalpha: a candidate mechanism for high-density lipoprotein-mediated repression of leukocyte adhesion. Circ Res. 2006 Mar 3;98(4):490-8 DOI: 10.1161/01.RES.0000205846.46812.be
Ettinger WH Jr, Sun WH, Binkley N, et al. Interleukin-6 causes hypocholesterolemia in middle-aged and old rhesus monkeys. J Gerontol A Biol Sci Med Sci. 1995 May;50(3):M137-40 DOI: 10.1093/gerona/50A.3.M137
Lazzerini PE, Lorenzini S, Selvi E, et al. Simvastatin inhibits cytokine production and nuclear factor-kB activation in interleukin 1ß-stimulated synoviocytes from rheumatoid arthritis patients. Clin Exp Rheum. 2007;25:696-700.
Yokota K, Mioyoshi F, Myazaki K, et al. High concentration simvastatin induces apoptosis in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol. 2008;35:193-200.
Gotsman I, Stabholz A, Planer D, et al. Serum cytokine tumor necrosis factor-alpha and interleukin-6 associated with the severity of coronary artery disease: indicators of an active inflammatory burden? Isr Med Assoc J. 2008 Jul;10(7):494-8.
Ridker PM. Targeting inflammatory pathways for the treatment of cardiovascular disease. Eur Heart J. 2014 Mar;35(9):540-3. Epub 2013 Nov 7 DOI: 10.1093/eurheartj/eht398
Cheng HF, Feng Y, Jiang DM, et al. Protective function of tocilizumab in human cardiac myocytes ischemia reperfusion injury. Asian Pac J Trop Med. 2015 Jan;8(1):48-52 DOI: 10.1016/S1995-7645(14)60186-3
Zimmermann O, Li K, Zaczkiewicz M, et al. C-reactive protein in human atherogenesis: facts and fiction. Mediators Inflamm. 2014;2014:561428. Epub 2014 Apr 1 DOI: 10.1155/2014/561428
Agrawal A, Gang TB, Rusinol AE. Recognition functions of pentameric C-reactive protein in cardiovascular disease. Mediators Inflamm. 2014;2014:319215. Epub 2014 May 19 DOI: 10.1155/2014/319215
Strang F, Schunkert H. C-reactive protein and coronary heart disease: all said -is not it? Mediators Inflamm. 2014;2014:757123. Epub 2014 Apr 7 DOI: 10.1155/2014/757123
Fu T, Borensztajn J. Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J. 2002 Aug 15;366(Pt 1):195-201 DOI: 10.1042/bj20020045
Wang MS, Black JC, Knowles MK, Reed SM. C-reactive protein (CRP) aptamer binds to monomeric but not pentameric form of CRP. Anal Bioanal Chem. 2011 Sep;401(4):1309-18 DOI: 10.1007/s00216-011-5174-1
Singh SK, Suresh MV, Hammond DJ Jr, et al. Binding of the monomeric form of C-reactive protein to enzymatically-modified low-density lipoprotein: effects of phosphoethanolamine. Clin Chim Acta. 2009 Aug;406(1-2):151-5 DOI: 10.1016/j.cca.2009.06.018
Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001 Mar 6;103(9):1194-7 DOI: 10.1161/01.CIR.103.9.1194
Manolov DE, Rö cker C, Hombach V, et al. Ultrasensitive confocal fluorescence microscopy of C-reactive protein interacting with FcgammaRIIa. Arterioscler Thromb Vasc Biol. 2004 Dec;24(12):2372-7 DOI: 10.1161/01.ATV.0000147407.17137.02
Li SF, Hu YW, Zhao JY, et al. Ox-LDL upregulates CRP expression through the IGF2 pathway in THP-1 macrophages. Inflammation. 2015 Apr;38(2):576-83 DOI: 10.1007/s10753-014-9964-4
Zhang YX, Cliff WJ, Schoefl GI, Higgins G. Coronary C-reactive protein distribution: its relation to development of Atherosclerosis. Atherosclerosis. 1999 Aug;145(2):375-9 DOI: 10.1016/S0021-9150(99)00105-7
Pegues MA, McCrory MA, Zarjou A, Szalai AJ. C-reactive protein exacerbates renal ischemia-reperfusion injury. Am J Physiol Renal Physiol. 2013 Jun 1;304(11):F1358-65 DOI: 10.1152/ajpre-nal.00476.2012
Anatoliotakis N, Deftereos S, Bouras G, et al. Myeloperoxidase: expressing inflammation and oxidative stress in cardiovascular disease. Curr Top Med Chem. 2013;13(2):115-38 DOI: 10.2174/1568026611313020004
Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med. 2000 Jun 15;28(12):1717-25 DOI: 10.1016/S0891-5849(00)00229-X
Brennan ML, Penn MS, van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003 Oct 23;349(17):1595-604 DOI: 10.1056/NEJMoa035003
Salonen I, Huttunen K, Hirvonen MR, et al. Serum myeloperoxidase is independent of the risk factors of atherosclerosis. Coron Artery Dis. 2012 Jun;23(4):251-8 DOI: 10.1097/MCA.0b013e328353a676
O'Flynn J, Dixon KO, Faber Krol MC, et al. Myeloperoxidase directs properdin-mediated complement activation. J Innate Immun. 2014;6(4):417-25. Epub 2013 Dec 20 DOI: 10.1159/000356980
Delporte C, van Antwerpen P, Vanhamme L, et al. Low-density lipoprotein modified by myeloperoxidase in inflammatory pathways and clinical studies. Mediators Inflamm. 2013;2013:971579. Epub 2013 Jul 24 DOI: 10.1155/2013/971579
Getz GS, Reardon CA. Myeloperoxidase-mediated dysfunctional high-density lipoprotein. Arterioscler Thromb Vasc Biol. 2014 Apr;34(4):695-6 DOI: 10.1161/ATVBAHA.114.303282
Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995 Dec;96(6):2758- 67 DOI: 10.1172/JCI118345
Van Lenten BJ, Wagner AC, Nayak DP, et al. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation. 2001 May 8;103(18):2283-8 DOI: 10.1161/01.CIR.103.18.2283
Watanabe J, Charles-Schoeman C, Miao Y, et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1828-37. Epub 2012 Jan 9 DOI: 10.1002/art.34363
Ansell BJ, Fonarow GC, Fogelman AM. The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol. 2007 Aug;18(4):427-34 DOI: 10.1097/MOL.0b013e3282364a17
Besler C, Heinrich K, Riwanto M, et al. High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease. Curr Pharm Des. 2010 May;16(13):1480-93 DOI: 10.2174/138161210791051013
Glomset JA. The plasma lecithin: cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-67.
Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 1973 Jun 29; 180(4093):1332-9 DOI: 10.1126/science.180.4093.1332
Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1975;1:16-9 DOI: 10.1016/S0140-6736(75)92376-4
Yamashita S, Sakai N, Hirano K, et al. Roles of plasma lipid transfer proteins in reverse cholesterol transport. Review. Front Biosci. 2001 Mar 1;6:D366-87.
Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol. 2010 Jun;21(3):229-38 DOI: 10.1097/MOL.0b013e328338472d
Ji Y, Jian B, Wang N, et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem. 1997 Aug 22;272(34):20982-5 DOI: 10.1074/jbc.272.34.20982
Attie AD, Kastelein JP, Hayden MR. Pivotal role of ABCA1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res. 2001 Nov;42(11):1717-26.
Brunham LR, Kruit JK, Iqbal J, et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest. 2006;116:1052-62 DOI: 10.1172/JCI27352
Von Eckardstein A, Chirazi A, Schuler-Lü ttmann S, et al. Plasma and fibroblasts of Tangier disease patients are disturbed in transferring phospholipids onto apolipoprotein A-I. J Lipid Res. 1998 May;39(5):987-98.
Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 2001 Jul;42(7):1007-17 DOI: 10.1101/gr.gr-1649r
Wang N, Silver DL, Thiele C, Tall AR. ATP-binding cassette transporter A1 (ABCA1) functions as a cholesterol efflux regulatory protein. J Biol Chem. 2001 Jun 29;276(26):23742-7 DOI: 10.1074/jbc.M102348200
Ragozin S, Niemeier A, Laatsch A, et al. Knockdown of hepatic ABCA1 by RNA interference decreases plasma HDL cholesterol levels and influences postprandial lipemia in mice. Arterioscler Thromb Vasc Biol. 2005;25:1433-8 DOI: 10.1161/01.ATV.0000166616.86723.d0
Yancey PG, de la Llera-Moya M, Swarnakar S, et al. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem. 2000 Nov 24;275(47):36596-604 DOI: 10.1074/jbc.M006924200
Yancey PG, de la Llera-Moya M, Drazul-Schrader D, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801 DOI: 10.1161/ATVBA-HA.109.199158
Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation. 2006;113(21):2548-55.
De la Llera-Moya M, Drazul-Schrader D, Asztalos BF, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010 Apr;30(4):796-801 DOI: 10.1161/ATVBA-HA.109.199158
Zhou H, Tan KCB, Shiu SWM, Wong Y. Cellular cholesterol efflux to serum is impaired in diabetic nephropathy. Diabetes Metab Res Rev. 2008;24:617-23 DOI: 10.1002/dmrr.895
Favari E, Lee M, Calabresi L, et al. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1-but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J Biol Chem. 2004;279:9930-6 DOI: 10.1074/jbc.M312476200
Ranganath VK, Maranian P, Elashoff DA, et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford). 2013 Oct;52(10):1809-17. Epub 2013 Jun 27 DOI: 10.1093/rheumatology/ket224
Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003 Mar 11;107(9):1303-7 DOI: 10.1161/01.CIR.0000054612.26458.B2
Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012 Sep;71(9):1524-9 DOI: 10.1136/annrheumdis-2011-200726
Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005 Feb;52(2):402-11 DOI: 10.1002/art.20853
Koivuniemi R, Paimela L, Suomalainen R, Leirisalo-Repo M. Cardiovascular diseases in patients with rheumatoid arthritis. Scand J Rheumatol. 2013;42(2):131-5. Epub 2012 Dec 18 DOI: 10.3109/03009742.2012.723747
Holmqvist ME, Wedren S, Jacobsson LT, et al. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med. 2010 Dec;268(6):578-85 DOI: 10.1111/j.1365-2796.2010.02260.x
Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010 Feb;69(2):325-31 DOI: 10.1136/ard.2009.113696
Dessein PH, Joffe BI. When is a patient with rheumatoid arthritis at risk for cardiovascular disease? J Rheumatol. 2006 Feb;33(2):201-3.
Kaplan MJ. Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment. Rheum Dis Clin North Am. 2010 May;36(2):405-26 DOI: 10.1016/j.rdc.2010.02.002
Zhang J, Chen L, Delzell E, et al. The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis. 2014 Jul;73(7):1301-8 DOI: 10.1136/annrheumdis-2013-204715
Hahn BH, Grossman J, Chen W, McMahon M. The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun. 2007 Mar-May;28(2-3):69-75. Epub 2007 Apr 16 DOI: 10.1016/j.jaut.2007.02.004
Lazarevic MB, Vitic J, Mladenovic V, et al. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum. 1992 Dec;22(3):172-8 DOI: 10.1016/0049-0172(92)90017-8
Dessein PH, Stanwix AE, Moomal Z. Rheumatoid arthritis and cardiovascular disease may share similar risk factors. Rheumatology (Oxford). 2001 Jun;40(6):703-4 DOI: 10.1093/rheumatology/40.6.703
Kim SH, Lee CK, Lee EY, et al. Serum oxidized low-density lipoproteins in rheumatoid arthritis. Rheumatol Int. 2004 Jul;24(4):230-3 DOI: 10.1007/s00296-003-0358-4
Myasoedova E, Crowson CS, Kremers HM, et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis. 2010 Jul;69(7):1310-4 DOI: 10.1136/ard.2009.122374
Liao KP, Cai T, Gainer VS, et al. Lipid and lipoprotein levels and trend in rheumatoid arthritis compared to the general population. Arthritis Care Res (Hoboken). 2013 Dec;65(12):2046-50 DOI: 10.1002/acr.22091
Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68:460-9 DOI: 10.1136/ard.2008.101964
Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoid and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis. 2003;62:842-5 DOI: 10.1136/ard.62.9.842
Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis. 2011 Mar;70(3):482-7 DOI: 10.1136/ard.2010.135871
Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment -a prospective, controlled study. Arthritis Res Ther. 2006;8(3):R82. Epub 2006 Apr 28 DOI: 10.1186/ar1952
Chavan VU, Ramavataram D, Patel PA, Rupani MP. Evaluation of serum magnesium, lipid profile and various biochemical parameters as risk factors of cardiovascular diseases in patients with rheumatoid arthritis. J Clin Diagn Res. 2015 Apr;9(4):BC01-5. Epub 2015 Apr 1 DOI: 10.7860/JCDR/2015/12206.5740
Van de Stadt LA, van Sijl AM, van Schaardenburg D, Nurmohamed MT. Dyslipidaemia in patients with seropositive arthralgia predicts the development of arthritis. Ann Rheum Dis. 2012;71:1915-6 DOI: 10.1136/annrheumdis-2012-201709
Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol. 1999 Aug;26(8):1701-4.
White D, Fayez S, Doube A. Atherogenic lipid profiles in rheumatoid arthritis. N Z Med J. 2006 Aug 18;119(1240):U2125.
Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis - the Third National Health and Nutrition Examination Survey. J Rheumatol. 2005 Dec;32(12):2311-6.
Govindan KP, Basha S, Ramesh V, et al. A comparative study on serum lipoprotein (a) and lipid profile between rheumatoid arthritis patients and normal subjects. J Pharm Bioallied Sci. 2015 Apr;7(Suppl 1):S22-5 DOI: 10.4103/0975-7406.155767
Attar SM. Hyperlipidemia in rheumatoid arthritis patients in Saudi Arabia. Correlation with C-reactive protein levels and disease activity. Saudi Med J. 2015 Jun;36(6):685-91 DOI: 10.15537/smj.2015.6.10557
Dessein PH, Stanwix AE, Joffe BI. Cardiovascular risk in rheumatoid arthritis versus osteoarthritis: acute phase response related decreased insulin sensitivity and high-density lipoprotein cholesterol as well as clustering of metabolic syndrome features in rheumatoid arthritis. Arthritis Res. 2002;4(5):R5 DOI: 10.1186/ar428
Hurt-Camejo E, Paredes S, Masana L, et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum. 2001 Dec;44(12):2761-7. doi: 10.1002/1529-0131(200112)44:123.0.CO;2-5
Boyer JF, Gourraud PA, Cantagrel A, et al. Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine. 2011 Mar;78(2):179-83. Epub 2010 Sep 17 DOI: 10.1016/j.jbspin.2010.07.016
Curtis JR, John A, Baser O. Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2012 Sep;64(9):1282-91 DOI: 10.1002/acr.21693
Gonzalez A, Maradit Kremers H, Crowson CS, et al. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? Ann Rheum Dis. 2008 Jan;67(1):64-9. Epub 2007 May 21 DOI: 10.1136/ard.2006.059980
Pozzi FS, Maranhao RC, Guedes LK, et al. Plasma kinetics of an LDL-like non-protein nanoemulsion and transfer of lipids to high-density lipoprotein (HDL) in patients with rheumatoid arthritis. J Clin Lipidol. 2015 Jan-Feb;9(1):72-80. Epub 2014 Nov 4 DOI: 10.1016/j.jacl.2014.10.004
Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011 Jan 13;364(2):127-35 DOI: 10.1056/NEJMoa1001689
Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014 Dec 18;371(25):2383-93. Epub 2014 Nov 18 DOI: 10.1056/NEJMoa1409065
Asztalos BF, Collins D, Cupples LA, et al. Value of high density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the veteran's affairs HDL Intervention trial. Aterioscler Throm Vasc Biol. 2005;25:2185-91 DOI: 10.1161/01.ATV.0000183727.90611.4f
Lamon-Fava S, Herrington DM, Reboussin DM, et al. Plasma levels of HDL subpopulations and remnant lipoproteins predict the extent of angiographically-defined coronary artery disease in postmenopausal women. Arterioscler Thromb Vasc Biol. 2008;28:575-9 DOI: 10.1161/ATVBAHA.107.157123
Watanabe H, Soderlund S, Soro-Paavonen A, et al. Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol. 2006;26:897-902 DOI: 10.1161/01.ATV.0000209577.04246.c0
Williams PT, Feldman DE. Prospective study of coronary heart disease vs. HDL2, HDL3, and other lipoproteins in Gofman's Livermore Cohort. Atherosclerosis. 2011 Jan;214(1):196-202. Epub 2010 Oct 23 DOI: 10.1016/j.atherosclerosis.2010.10.024
Superko HR, Pendyala L, Williams PT, et al. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol. 2012 Nov-Dec;6(6):496-523. Epub 2012 Mar 23 DOI: 10.1016/j.jacl.2012.03.001
Arts E, Fransen J, Lemmers H, et al. High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study. Arthritis Res Ther. 2012 May 14;14(3):R116 DOI: 10.1186/ar3842
Van Lenten BJ, Hama SY, de Beer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995 Dec;96(6):2758-
McMahon M, Grossman J, FitzGerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 2006 Aug;54(8):2541-9 DOI: 10.1002/art.21976
Charles-Schoeman C, Watanabe J, Lee YY, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 2009 Oct;60(10):2870-9 DOI: 10.1002/art.24802
Watanabe J, Charles-Schoeman C, Miao Y, et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1828-37. Epub 2012 Jan 9 DOI: 10.1002/art.34363
Feijoo M, Tunez I, Ruiz A, et al. Oxidative stress biomarkers as indicator of chronic inflammatory joint diseases stage. Reumatol Clin. 2010 Mar-Apr;6(2):91-4. Epub 2009 Jul 31 DOI: 10.1016/j.reuma.2008.12.016
Vivekanandan-Giri A, Slocum JL, Byun J, et al. High density lipoprotein is targeted for oxidation by myeloperoxidase in rheumatoid arthritis. Ann Rheum Dis. 2013 Oct;72(10):1725-31. Epub 2013 Jan 12 DOI: 10.1136/annrheumdis-2012-202033
Wang W, Jian Z, Guo J, Ning X. Increased levels of serum myeloperoxidase in patients with active rheumatoid arthritis. Life Sci. 2014 Nov 4;117(1):19-23. Epub 2014 Sep 28 DOI: 10.1016/j.lfs.2014.09.012
Nzeusseu Toukap A, Delporte C, Noyon C, et al. Myeloperoxidase and its products in synovial fluid of patients with treated or untreated rheumatoid arthritis. Free Radic Res. 2014 Apr;48(4):461-5. Epub 2014 Feb 20 DOI: 10.3109/10715762.2014.886327
Charles-Schoeman C, Lee YY, Grijalva V, et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2012 Jul;71(7):1157-62. Epub 2012 Jan 20 DOI: 10.1136/annrheumdis-2011-200493
Robins SJ, Lyass A, Brocia RW, et al. Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study. Atherosclerosis. 2013 May;228(1):230-6. 2013.01.046. Epub 2013 Feb 18 DOI: 10.1016/j.atherosclerosis
Ferraz-Amaro I, Gonzalez-Gay MA, Garcia-Dopico JA, Diaz-Gonzalez F. Cholesteryl ester transfer protein in patients with rheumatoid arthritis. J Rheumatol. 2013 Jul;40(7):1040-7. Epub 2013 May 15 DOI: 10.3899/jrheum.121507
Voloshyna I, Modayil S, Littlefield MJ, et al. Plasma from rheumatoid arthritis patients promotes pro-atherogenic cholesterol transport gene expression in THP-1 human macrophages. Exp Biol Med (Maywood). 2013 Oct;238(10):1192-7. Epub 2013 Sep 2 DOI: 10.1177/1535370213503262
Liao KP, Playford MP, Frits M, et al. The association between reduction in inflammation and changes in lipoprotein levels and HDL cholesterol efflux capacity in rheumatoid arthritis. J Am Heart Assoc. 2015 Jan 30;4(2). pii: e001588 DOI: 10.1161/JAHA.114.001588
Navarro-Millan I, Yang S, DuVall SL, et al. Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration. Ann Rheum Dis. 2016 Feb;75(2):341-7. Epub 2015 Jan 21 DOI: 10.1136/annrheumdis-2013-204987
Климов АН, Никульчева НГ. Обмен липидов и липопротеидов и его нарушения. Cанкт-Петербург: Питер; 1999
Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331
Попкова ТВ, Новикова ДС, Писарев ВВидр. Факторы риска кардиоваскулярных заболеваний при ревматоидном артрите. Научно-практическая ревматология. 2009;47(3):4-11
Попкова ТВ, Новикова ДС, Новиков ААидр. Роль нарушений в системе транспорта холестерина крови в развитие атеросклероза при ревматоидном артрите. Научно-практическая ревматология. 2007;45(5):4-10

Еще

Статья обзорная